MX2022004779A - Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. - Google Patents
Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia.Info
- Publication number
- MX2022004779A MX2022004779A MX2022004779A MX2022004779A MX2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- receptor agonists
- dementia
- semaglutide
- subjects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a terapias médicas mejoradas para todas las formas y etapas de demencia que implican la administración de (i) agonistas del receptor de GLP-1 a sujetos con síndrome metabólico o (ii) semaglutida.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19207501 | 2019-11-06 | ||
EP20186623 | 2020-07-20 | ||
PCT/EP2020/081087 WO2021089678A1 (en) | 2019-11-06 | 2020-11-05 | Glp-1 receptor agonists in dementia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004779A true MX2022004779A (es) | 2022-06-14 |
Family
ID=73172681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004779A MX2022004779A (es) | 2019-11-06 | 2020-11-05 | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20220280612A1 (es) |
EP (1) | EP4054620B1 (es) |
JP (1) | JP2023500032A (es) |
KR (1) | KR20220110731A (es) |
CN (1) | CN114728042A (es) |
AU (1) | AU2020377469A1 (es) |
BR (1) | BR112022007721A2 (es) |
CA (1) | CA3154744A1 (es) |
IL (1) | IL291876A (es) |
MX (1) | MX2022004779A (es) |
TW (1) | TW202118509A (es) |
WO (1) | WO2021089678A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220132606A (ko) * | 2020-01-30 | 2022-09-30 | 일라이 릴리 앤드 캄파니 | 둘라글루티드의 치료 용도 |
JP2024500410A (ja) * | 2020-12-16 | 2024-01-09 | ザ チャイニーズ ユニバーシティー オブ ホンコン | 老化脳機能低下を逆転する方法 |
AU2022400245A1 (en) | 2021-12-02 | 2024-05-30 | Københavns Universitet | Peptide-drug conjugates for treatment of neurodegenerative diseases |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
EP1149066B1 (en) | 1999-02-05 | 2005-11-09 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
US8927015B2 (en) | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
US7544833B2 (en) | 2006-09-07 | 2009-06-09 | Hoffmann-La Roche Inc. | Methods for producing N-(8-[2-hydroxybenzoyl]-amino) caprylic acid |
CN102791731B (zh) | 2009-12-16 | 2016-04-20 | 诺沃—诺迪斯克有限公司 | Glp-1类似物和衍生物 |
RS56998B1 (sr) * | 2010-12-16 | 2018-05-31 | Novo Nordisk As | Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
WO2012140117A1 (en) | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
CA2877056A1 (en) * | 2012-07-01 | 2014-01-09 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
JP6768515B2 (ja) | 2014-04-07 | 2020-10-14 | ノヴォ ノルディスク アー/エス | 二重アシル化glp−1化合物 |
US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
US11123405B2 (en) * | 2015-12-23 | 2021-09-21 | The Johns Hopkins University | Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions |
US20190142905A1 (en) * | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
-
2020
- 2020-11-05 CN CN202080076976.0A patent/CN114728042A/zh active Pending
- 2020-11-05 AU AU2020377469A patent/AU2020377469A1/en active Pending
- 2020-11-05 EP EP20803489.2A patent/EP4054620B1/en active Active
- 2020-11-05 MX MX2022004779A patent/MX2022004779A/es unknown
- 2020-11-05 KR KR1020227015440A patent/KR20220110731A/ko active Search and Examination
- 2020-11-05 IL IL291876A patent/IL291876A/en unknown
- 2020-11-05 WO PCT/EP2020/081087 patent/WO2021089678A1/en active Application Filing
- 2020-11-05 CA CA3154744A patent/CA3154744A1/en active Pending
- 2020-11-05 JP JP2022521146A patent/JP2023500032A/ja active Pending
- 2020-11-05 BR BR112022007721A patent/BR112022007721A2/pt unknown
- 2020-11-06 TW TW109138851A patent/TW202118509A/zh unknown
-
2022
- 2022-05-04 US US17/736,116 patent/US20220280612A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,485 patent/US20230302094A1/en not_active Abandoned
-
2024
- 2024-01-30 US US18/426,412 patent/US20240207364A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023500032A (ja) | 2023-01-04 |
WO2021089678A1 (en) | 2021-05-14 |
TW202118509A (zh) | 2021-05-16 |
EP4054620B1 (en) | 2024-05-29 |
US20230302094A1 (en) | 2023-09-28 |
US20220280612A1 (en) | 2022-09-08 |
US20240207364A1 (en) | 2024-06-27 |
BR112022007721A2 (pt) | 2022-07-12 |
IL291876A (en) | 2022-06-01 |
CN114728042A (zh) | 2022-07-08 |
CA3154744A1 (en) | 2021-05-14 |
EP4054620C0 (en) | 2024-05-29 |
KR20220110731A (ko) | 2022-08-09 |
AU2020377469A1 (en) | 2022-04-28 |
EP4054620A1 (en) | 2022-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004779A (es) | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. | |
PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
MX2022004374A (es) | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer. | |
MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
MX2020010689A (es) | Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion. | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
MX2021005382A (es) | Vehiculos derivados de cholix para suministro oral de carga util heterologa. | |
PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
MY191321A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
MX2018000362A (es) | Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon. | |
MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
GB201201314D0 (en) | Composition | |
PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
BR112021009856A8 (pt) | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l | |
MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
PH12021551540A1 (en) | Anti-il-36r antibodies for treatment of palmoplantar pustulosis | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
MX2018001849A (es) | Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo. | |
ECSP20000655A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
MX2018012800A (es) | Administracion de metabolitos de berberina. |